Skip to Main Content.
Site navigation
Fidelity.com Home
  • Customer Service
  • Profile
  • Open an Account
  • Refer a Friend
  • Log In
  • Customer Service
  • Profile
  • Open an Account
  • Refer a Friend
  • Log Out
  • Accounts & Trade
    • Portfolio Log In Required
    • Portfolio
    • AccountPositions Log In Required
    • AccountPositions
    • Trade Log In Required
    • Trade
    • Active Trader Pro
    • Transfers
    • Cash Management Log In Required
    • Cash Management
    • BillPay Log In Required
    • BillPay
    • Full View Log In Required
    • Full View
    • Security Settings Log In Required
    • Security Settings
    • Account Features Log In Required
    • Account Features
    • Statements Log In Required
    • Statements
    • Tax Forms & Information
    • Retirement DistributionsLog In Required
    • Fidelity Rewards+Log In Required
    • New Account ChecklistLog In Required
  • Planning & Advice
    • What We Offer
    • My Goals
    • Financial Basics
    • Building Savings
    • Digital Investing & Advice
    • Wealth Management
    • Find an advisor
    • Retirement
    • Life Events
  • News & Research
    • News
    • Watch List Log In Required
    • Quotes
    • Quotes
    • Alerts Log In Required
    • Mutual Funds
    • Stocks
    • Fixed Income, Bonds & CDs
    • ETFs
    • Options
    • Markets & Sectors
    • IPOs
    • Annuities
    • Learning Center
    • Notebook
    • Notebook
  • Investment Products
    • Mutual Funds
    • Retirement & IRAs
    • Trading
    • Stocks
    • Fixed Income, Bonds & CDs
    • ETFs
    • Options
    • Sector Investing
    • Cash Management & Credit Cards
    • Managed Accounts
    • 529 College Savings
    • Health Savings Account
    • Annuities
    • Life Insurance & Long Term Care
    • Charitable Giving
  • Why Fidelity
    • The Fidelity Advantage
    • Planning & Advice
    • Trading
    • Straightforward Pricing
    • Insights & Tools
    • Security & Protection
    • About Fidelity
    • Careers
  • Customer Service
  • Profile
  • Open an Account
  • Refer a Friend
  • Log In
  • Customer Service
  • Profile
  • Open an Account
  • Refer a Friend
  • Log Out
Content and data provided by various third parties and Fidelity − Terms of Use
  • Research >
  • Stocks >
  • News & Events >

Stock Details


Find Symbol. Opens in new window.
  • Snapshot
  • Detailed Quote
  • Advanced Chart &
    Technical Analysis Opens in New Window
  • News & Events
  • Compare
  • Analyst Opinions
  • Research Reports
  • Key Statistics
  • Earnings
  • Dividends
  • Ownership & Insiders
  • Financial Statements
  • SEC Filings

RELATED RESOURCES

  • Stock Research Overview
  • Stock Screeners
  • Markets & Sectors
  • Fidelity Learning Center Opens in New Window
Print Format
Change Text Size:
  • Default text sizeA
  • Larger text sizeA
  • Largest text sizeA

Assembly Biosciences CEO Dr. John McHutchison Named Recipient of the Prestigious Advance 2020 Global Impact Award

BY GlobeNewswire
— 8:00 AM ET 10/15/2020

SOUTH SAN FRANCISCO, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (ASMB) , a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that John McHutchison AO, MD – the company’s CEO and president– was named the recipient of the Advance 2020 Global Impact award. The Advance awards recognize the work of remarkable global Australians making an extraordinary impact worldwide.

The award honors Dr. McHutchison’s innovative work in developing life-changing and curative therapies for patients with hepatitis C virus (HCV). These treatments are in part a result of his 30-year personal investment researching and developing therapeutics for this previously incurable disease. Now at the helm of Assembly Biosciences (ASMB), Dr. McHutchison is dedicated to pioneering a new class of therapeutics for HBV, which impacts approximately 250 million people globally.

“It is a great honor to be named a winner of this highly prestigious award,” said Dr. McHutchison. “There are a quarter of a billion people worldwide who are chronically infected with HBV and deserve better outcomes, as have now been delivered for people with HCV infection. Having my contributions to the HCV field recognized by the Advance awards commission is truly inspiring and reinforces my commitment and confidence that we can achieve a future with curative treatment regimens for patients with HBV infection.”

In its ninth year, the Advance Awards celebrates Australian global leaders that represent an extraordinary group of talented innovators who have demonstrated excellence in their respective fields on the global stage, ranging from technology innovation, financial services and healthcare, to social impact, sustainability, and the arts. The Awards are the only of their kind that recognize the contributions of the one million Australians living abroad.

The full list of Advance 2020 award recipients is available at www.advance.org/advance-awards. More information about Assembly Biosciences (ASMB) is available at www.assemblybio.com.

About Assembly Biosciences (ASMB)
Assembly Biosciences, Inc. (ASMB) is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome. The HBV program is focused on advancing a new class of potent, oral core inhibitors that have the potential to increase cure rates for chronically infected patients. The microbiome program is developing novel oral live microbial biotherapeutic candidates with Assembly’s fully integrated platform, including a robust process for strain identification and selection, GMP manufacturing expertise and targeted delivery to the lower gastrointestinal tract with the GEMICEL® technology For more information, visit assemblybio.com.

 


Investor Contact
Assembly Biosciences, Inc. (ASMB)
Lauren Glaser
Senior Vice President, Investor Relations and Corporate Affairs
(415) 521-3828
lglaser@assemblybio.com

Media Contact
Sam Brown Inc.
Audra Friis
(917) 519-9577
ASMBMedia@sambrown.com

Image: AssemblyBio_logo_RGB.png

Source: Assembly Biosciences, Inc. (ASMB)

More ASMB News

  • Assembly Biosciences Announces October Conference Participation
    GlobeNewswire - 7:30 AM ET 10/05/2020
  • Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    GlobeNewswire - 4:30 PM ET 10/02/2020
  • Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    GlobeNewswire - 4:30 PM ET 09/04/2020
Fidelity Investments. Copyright 1998–2021 FMR LLC. 
All rights reserved. 

  • Terms of Use|
  • Privacy|
  • Security|
  • Site Map 
Close